Spironolactone-induced inhibition of aldosterone biosynthesis in primary aldosteronism: Morphological and functional studies
dc.contributor.author | Conn, Jerome W. | en_US |
dc.contributor.author | Hinerman, Dorin L. | en_US |
dc.date.accessioned | 2006-04-07T17:07:44Z | |
dc.date.available | 2006-04-07T17:07:44Z | |
dc.date.issued | 1977-12 | en_US |
dc.identifier.citation | Conn, J. W., Hinerman, D. L. (1977/12)."Spironolactone-induced inhibition of aldosterone biosynthesis in primary aldosteronism: Morphological and functional studies." Metabolism 26(12): 1293-1307. <http://hdl.handle.net/2027.42/22806> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6WN4-4C4FMGH-CG/2/7e7e4d29566a5b4d2f6eed660df575d9 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/22806 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=927164&dopt=citation | en_US |
dc.description.abstract | Twenty-five patients harboring aldosterone-producing adenomas were treated with spironolactone for 2-170 days immediately preoperatively. In the early period of administration of the drug (up to 27 days), plasma and urinary aldosterone decreased sharply while plasma renin activity (PRA) and serum potassium were rising. During this period of time, spironolactone bodies (SB), which form exclusively in cells actively producing aldosterone, were forming rapidly in the tumor cells but not in the inactive glomerulosa cells proper. The SB appear to be a morphological expression of a block in aldosterone biosynthesis. Since SB do not occur in normal fasciculata cells, which, like glomerulosa cells, also synthesize corticosterone, it is concluded that spironolactone inhibition of aldosterone biosynthesis occurs between corticosterone and aldosterone. Recent studies in vitro by others have suggested that the inhibition occurs at the corticosterone-methyl oxidase step, I (Ulick's nomenclature). The great diuresis of sodium and retention of potassium resulting from continued administration of the drug sharply activates aldosterone stimulatory factors. Aldosterone production may return to baseline levels in several weeks but it is inappropriately low in relation to the levels of PRA and serum potassium. With the further passage of time (average 4-6 wk), aldosterone production may increase 50%-100% above baseline levels, suggesting that the block has disappeared or is receding. At this time SB are diminishing in number and by 170 days of the drug they have virtually disappeared. We have hypothesized, among other possibilities, that recovery of the ability to convert corticosterone to aldosterone occurs by virtue of a mechanism activated by sodium deficiency, independent of angiotensin, which stimulates step 1 of the corticosterone-methyl oxidase system. As the block in the final step(s) of the biosynthetic pathway recedes, the existing elevated levels of angiotensin become much more effective in stimulating the production of aldosterone. | en_US |
dc.format.extent | 1124632 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Spironolactone-induced inhibition of aldosterone biosynthesis in primary aldosteronism: Morphological and functional studies | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine (Division of Endocrinology and Metabolism and the Metabolism Research Unit), the University of Michigan Medical School, Ann Arbor, Mich., USA; the Department of Pathology, the University of Michigan Medical School, Ann Arbor, Mich., USA; the Veterans Administration Hospital, Ann Arbor, Mich., USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine (Division of Endocrinology and Metabolism and the Metabolism Research Unit), the University of Michigan Medical School, Ann Arbor, Mich., USA; the Department of Pathology, the University of Michigan Medical School, Ann Arbor, Mich., USA; the Veterans Administration Hospital, Ann Arbor, Mich., USA | en_US |
dc.identifier.pmid | 927164 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/22806/1/0000363.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0026-0495(77)90026-9 | en_US |
dc.identifier.source | Metabolism | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.